Literature DB >> 9236752

Reduction in length of hospital stay for acute childhood asthma associated with the introduction of casemix funding.

M South1.   

Abstract

OBJECTIVE: To examine changes to hospital admission rates, length of stay (LOS), bed use, and unplanned readmission rates for children with acute exacerbations of asthma following the change of the Victorian health care system to casemix funding.
SETTING: Large university-affiliated children's hospital in Melbourne, Victoria.
DESIGN: Prospective collection of data from July 1989 to June 1996 for all children admitted with acute asthma (n = 11939).
RESULTS: The number of admissions for acute asthma showed a rising trend before the introduction of casemix funding in July 1993, and subsequently fell. There was a significant fall in mean LOS (64.5 to 39 hours; -40%; P = 0.001), and hence in bed-hours occupied for asthma (115370 to 61116; -47%; P = 0.001). There were no increases in unplanned readmission rates for asthma within the next seven or 14 days.
CONCLUSION: LOS and bed use for acute asthma at our hospital have been significantly reduced since the introduction of casemix funding, although this study does not prove a causal relationship. There was no increase in readmission rates, and thus no suggestion of any adverse effects as a result of reducing LOS. The 47% reduction in bed-hours should lead to large reductions in cost to the hospital.

Entities:  

Mesh:

Year:  1997        PMID: 9236752

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Successful implementation of spacer treatment guideline for acute asthma.

Authors:  C V Powell; G R Maskell; M K Marks; M South; C F Robertson
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

Review 2.  Activity-based funding of hospitals and its impact on mortality, readmission, discharge destination, severity of illness, and volume of care: a systematic review and meta-analysis.

Authors:  Karen S Palmer; Thomas Agoritsas; Danielle Martin; Taryn Scott; Sohail M Mulla; Ashley P Miller; Arnav Agarwal; Andrew Bresnahan; Afeez Abiola Hazzan; Rebecca A Jeffery; Arnaud Merglen; Ahmed Negm; Reed A Siemieniuk; Neera Bhatnagar; Irfan A Dhalla; John N Lavis; John J You; Stephen J Duckett; Gordon H Guyatt
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.